After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a nonproliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in several sought-after ophthalmology indications. But EyePoint appears to have reversed its fortunes thanks to positive new interim data on its lead asset in diabetic macular edema (DME).